Literature DB >> 15568132

[Treatment of therapy-resistant acral ulcers with iloprost].

S von Schmiedeberg1, S Artik, T Assmann, M Megahed, T Ruzicka.   

Abstract

Patients with systemic sclerosis (SSc) develop often acral ulcers which are resistant to therapy and may result in gangrene and amputation. We investigated the effects of iloprost infusion on the acral ulcers and necrosis in patients with five patients with SSc and one with mixed connective tissue disease who had been previously treated with various modalities without improvement. All patients had Raynaud phenomenon, acral ulcers and necrosis. Iloprost 25 microg per day was administered intravenously daily over six hours for ten consecutive days. Eight weeks later all patients were treated with a second iloprost therapy cycle for five days. Two patients with severe ulceration received a third cycle until remission occurred. In all cases acral ulcers healed completely and no patient relapsed during an observation period of 6 months.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15568132     DOI: 10.1007/s00105-004-0844-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  18 in total

1.  Why everything (or nothing) seems to work in the treatment of scleroderma.

Authors:  J R Seibold; D E Furst; P J Clements
Journal:  J Rheumatol       Date:  1992-05       Impact factor: 4.666

2.  Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules.

Authors:  S Della Bella; M Molteni; C Mocellin; S Fumagalli; P Bonara; R Scorza
Journal:  Prostaglandins Other Lipid Mediat       Date:  2001-06       Impact factor: 3.072

Review 3.  Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

Authors:  B Kahaleh; M Matucci-Cerinic
Journal:  Arthritis Rheum       Date:  1995-01

Review 4.  [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].

Authors:  G Riemekasten; H Jepsen; G R Burmester; F Hiepe
Journal:  Z Rheumatol       Date:  1998-04       Impact factor: 1.372

5.  Immunogenetic associations of scleroderma-related antinuclear antibodies.

Authors:  E Genth; R Mierau; P Genetzky; C A von Mühlen; S Kaufmann; H von Wilmowsky; M Meurer; T Krieg; H J Pollmann; P W Hartl
Journal:  Arthritis Rheum       Date:  1990-05

6.  Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

Authors:  G P Rodnan; R L Myerowitz; G O Justh
Journal:  Medicine (Baltimore)       Date:  1980-11       Impact factor: 1.889

7.  [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].

Authors:  E Cordioli; S Virgilio; R Ghirardi; M Martinelli
Journal:  Minerva Med       Date:  1992-11       Impact factor: 4.806

Review 8.  Measuring disease activity and severity in scleroderma.

Authors:  P J Clements
Journal:  Curr Opin Rheumatol       Date:  1995-11       Impact factor: 5.006

Review 9.  Systemic scleroderma. Clinical and pathophysiologic aspects.

Authors:  T Krieg; M Meurer
Journal:  J Am Acad Dermatol       Date:  1988-03       Impact factor: 11.527

10.  Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.

Authors:  D E Furst; P J Clements; S Hillis; P A Lachenbruch; B L Miller; M G Sterz; H E Paulus
Journal:  Arthritis Rheum       Date:  1989-05
View more
  2 in total

1.  [Treatment options of acral ulcers in MCTD].

Authors:  Ann-Kristin Herink; Lars Köthe; Matthias Girndt; Gernot Keysser
Journal:  Med Klin (Munich)       Date:  2010-12-07

2.  [Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil].

Authors:  E Friedrichson; P Rehberger; J T Fuhrmann; F Walz; M Meurer; C Pfeiffer
Journal:  Hautarzt       Date:  2008-03       Impact factor: 1.198

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.